Author:
Tomizawa D,Tawa A,Watanabe T,Saito A M,Kudo K,Taga T,Iwamoto S,Shimada A,Terui K,Moritake H,Kinoshita A,Takahashi H,Nakayama H,Koh K,Kigasawa H,Kosaka Y,Miyachi H,Horibe K,Nakahata T,Adachi S
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference13 articles.
1. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543–552.
2. Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009; 27: 4007–4013.
3. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, von Neuhoff C, Sander A et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 2011; 118: 5409–5415.
4. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896–903.
5. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer research 1998; 58: 4173–4179.
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献